532814 Sigma-AldrichMDM2 Inhibitor, SP-141 - CAS 1253491-42-7 - Calbiochem
A cell-permeable compound that binds to MDM2 with high affinity (Ki = 28 nM) and inhibits its activity in multiple breast cancer cell lines, independent of their p53 status.
More>> A cell-permeable compound that binds to MDM2 with high affinity (Ki = 28 nM) and inhibits its activity in multiple breast cancer cell lines, independent of their p53 status. Less<<Synonyms: SP141, SP 141
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 1253491-42-7 | C₂₂H₁₆N₂O |
Pricing & Availability
| Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
|---|---|---|---|---|---|---|
| 5328140001 |
|
Glass bottle | 10 mg |
|
— |
| References | |
|---|---|
| References | Wang, W., et al. 2014. Nat. Comm. 5, 5086. |
| Product Information | |
|---|---|
| CAS number | 1253491-42-7 |
| Form | Yellow powder |
| Hill Formula | C₂₂H₁₆N₂O |
| Chemical formula | C₂₂H₁₆N₂O |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | MDM2 |
| Primary Target K<sub>i</sub> | 28 nM |
| Purity | ≥97% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 5328140001 | 04055977281927 |
Documentation
MDM2 Inhibitor, SP-141 - CAS 1253491-42-7 - Calbiochem SDS
| Title |
|---|
References
| Reference overview |
|---|
| Wang, W., et al. 2014. Nat. Comm. 5, 5086. |
Technical Info
| Title |
|---|
| Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
| White Paper: Further considerations of antibody validation and usage. |



